Published in J Clin Microbiol on July 01, 1995
Epidemiological evidence for dormant Cryptococcus neoformans infection. J Clin Microbiol (1999) 2.78
Molecular epidemiology of Cryptococcus neoformans in Brazil and the United States: evidence for both local genetic differences and a global clonal population structure. J Clin Microbiol (1997) 2.19
Molecular subtype distribution of Cryptococcus neoformans in four areas of the United States. Cryptococcal Disease Active Surveillance Group. J Clin Microbiol (1996) 2.08
Concordance of clinical and environmental isolates of Cryptococcus neoformans var. gattii by random amplification of polymorphic DNA analysis and PCR fingerprinting. J Clin Microbiol (1996) 1.63
Karyotype instability in Cryptococcus neoformans infection. J Clin Microbiol (1996) 1.53
Persistence, replacement, and microevolution of Cryptococcus neoformans strains in recurrent meningitis in AIDS patients. J Clin Microbiol (1996) 1.44
Random amplified polymorphic DNA analysis of clinically and environmentally isolated Cryptococcus neoformans in Nagasaki. J Clin Microbiol (1995) 1.36
Emerging disease issues and fungal pathogens associated with HIV infection. Emerg Infect Dis (1996) 1.17
Serotyping of Cryptococcus neoformans strains isolated from clinical specimens in Thailand and their susceptibility to various antifungal agents. Eur J Epidemiol (1997) 1.10
Cryptococcus gattii infections in multiple states outside the US Pacific Northwest. Emerg Infect Dis (2013) 1.09
DNA typing suggests pigeon droppings as a source of pathogenic Cryptococcus neoformans serotype D. J Clin Microbiol (1997) 1.06
Variation in electrophoretic karyotype and antifungal susceptibility of clinical isolates of Cryptococcus neoformans at a university-affiliated teaching hospital from 1987 to 1994. J Clin Microbiol (1998) 1.04
New PCR primer pairs specific for Cryptococcus neoformans serotype A or B prepared on the basis of random amplified polymorphic DNA fingerprint pattern analyses. J Clin Microbiol (1999) 1.01
Most cases of cryptococcal meningitis in HIV-uninfected patients in Vietnam are due to a distinct amplified fragment length polymorphism-defined cluster of Cryptococcus neoformans var. grubii VN1. J Clin Microbiol (2010) 0.89
Genetic multilocus studies of different strains of Cryptococcus neoformans: taxonomy and genetic structure. J Clin Microbiol (1999) 0.85
Genetic relatedness and diversity of Cryptococcus neoformans strains in the Maltese Islands. J Clin Microbiol (1997) 0.80
Isolation and Characterization of Cryptococcus neoformans from Environmental Sources in Busan. Mycobiology (2005) 0.79
Detection of specific sequences among DNA fragments separated by gel electrophoresis. J Mol Biol (1975) 503.08
Improved diagnostic medium for separation of Cryptococcus neoformans var. neoformans (serotypes A and D) and Cryptococcus neoformans var. gattii (serotypes B and C). J Clin Microbiol (1982) 6.78
Epidemiologic differences between the two varieties of Cryptococcus neoformans. Am J Epidemiol (1984) 5.74
Serologic grouping of Cryptococcus neoformans. Proc Soc Exp Biol Med (1968) 4.97
Separation of chromosomes of Cryptococcus neoformans by pulsed field gel electrophoresis. Infect Immun (1989) 3.86
Natural habitat of Cryptococcus neoformans var. gattii. J Clin Microbiol (1990) 3.47
Persistence of initial infection in recurrent Cryptococcus neoformans meningitis. Lancet (1993) 3.34
Hybridization probes for conventional DNA fingerprinting used as single primers in the polymerase chain reaction to distinguish strains of Cryptococcus neoformans. J Clin Microbiol (1993) 2.78
Restriction fragment length polymorphism analysis of Cryptococcus neoformans isolates from environmental (pigeon excreta) and clinical sources in New York City. J Clin Microbiol (1994) 2.43
Molecular and genetic analysis of URA5 transformants of Cryptococcus neoformans. Infect Immun (1992) 2.32
Restriction fragment polymorphism in mitochondrial DNA of Cryptococcus neoformans. J Gen Microbiol (1989) 2.28
Use of a dispersed repetitive DNA element to distinguish clinical isolates of Cryptococcus neoformans. J Clin Microbiol (1992) 2.27
DNA probe for strain typing of Cryptococcus neoformans. J Clin Microbiol (1992) 2.12
Extensive allelic variation in Cryptococcus neoformans. J Clin Microbiol (1992) 2.06
Electrophoretic karyotype of the pathogenic yeast Cryptococcus neoformans. J Gen Microbiol (1989) 2.02
Antigenic variation within serotypes of Cryptococcus neoformans detected by monoclonal antibodies specific for the capsular polysaccharide. Infect Immun (1989) 1.87
Virulence, serotype, and molecular characteristics of environmental strains of Cryptococcus neoformans var. gattii. Infect Immun (1992) 1.86
Serotyping of Cryptococcus neoformans by using a monoclonal antibody specific for capsular polysaccharide. J Clin Microbiol (1993) 1.80
Rapid method to extract DNA from Cryptococcus neoformans. J Clin Microbiol (1991) 1.78
Development of DNA probes for early diagnosis and epidemiological study of cryptococcosis in AIDS patients. J Clin Microbiol (1992) 1.51
Multilocus enzyme typing of Cryptococcus neoformans. J Clin Microbiol (1993) 1.50
Molecular typing of Cryptococcus neoformans serotype D clinical isolates. J Clin Microbiol (1994) 1.39
Isolation of Cryptococcus neoformans from houses of AIDS-associated cryptococcosis patients in Bujumbura (Burundi). AIDS (1989) 0.93
Glucuronoxylomannan of Cryptococcus neoformans obtained from patients with AIDS. Carbohydr Res (1993) 0.90
Isolation of saprophytic Cryptococcus neoformans var. neoformans in Kinshasa, Zaïre. Ann Soc Belg Med Trop (1986) 0.84
Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis (2001) 12.73
A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. Candidemia Study Group and the National Institute. N Engl J Med (1994) 9.11
Improved diagnostic medium for separation of Cryptococcus neoformans var. neoformans (serotypes A and D) and Cryptococcus neoformans var. gattii (serotypes B and C). J Clin Microbiol (1982) 6.78
Prognostic factors in cryptococcal meningitis. A study in 111 cases. Ann Intern Med (1974) 6.75
A new genus, filobasidiella, the perfect state of Cryptococcus neoformans. Mycologia (1976) 6.24
A rare genotype of Cryptococcus gattii caused the cryptococcosis outbreak on Vancouver Island (British Columbia, Canada). Proc Natl Acad Sci U S A (2004) 6.21
Aspergillosis. The spectrum of the disease in 98 patients. Medicine (Baltimore) (1970) 5.98
A comparison of amphotericin B alone and combined with flucytosine in the treatment of cryptoccal meningitis. N Engl J Med (1979) 5.87
Variables influencing susceptibility testing of Cryptococcus neoformans to 5-fluorocytosine. Antimicrob Agents Chemother (1973) 5.84
Epidemiologic differences between the two varieties of Cryptococcus neoformans. Am J Epidemiol (1984) 5.74
A pharmacologic guide to the clinical use of amphotericin B. J Infect Dis (1969) 5.58
Melanin-lacking mutants of Cryptococcus neoformans and their virulence for mice. J Bacteriol (1982) 5.40
Results of a survey of antifungal susceptibility tests in the United States and interlaboratory comparison of broth dilution testing of flucytosine and amphotericin B. J Clin Microbiol (1986) 5.19
Serologic grouping of Cryptococcus neoformans. Proc Soc Exp Biol Med (1968) 4.97
Encapsulation and melanin formation as indicators of virulence in Cryptococcus neoformans. Infect Immun (1986) 4.91
Taxonomic studies on Filobasidiella species and their anamorphs. Antonie Van Leeuwenhoek (1982) 4.90
Morphogenesis of Filobasidiella neoformans, the sexual state of Cryptococcus neoformans. Mycologia (1977) 4.83
Correlation of in vitro susceptibility test results with in vivo response: flucytosine therapy in a systemic candidiasis model. J Infect Dis (1983) 4.42
Chronic mucocutaneous candidiasis: model-building in cellular immunity. Ann Intern Med (1971) 4.41
Complementation of a capsule-deficient mutation of Cryptococcus neoformans restores its virulence. Mol Cell Biol (1994) 4.22
Chemotherapy of systemic mycoses (first of two parts). N Engl J Med (1974) 4.20
Epidemiologic differences among serotypes of Cryptococcus neoformans. Am J Epidemiol (1977) 3.91
Isolation of the URA5 gene from Cryptococcus neoformans var. neoformans and its use as a selective marker for transformation. Mol Cell Biol (1990) 3.91
Susceptibility to 5-fluorocytosine and prevalence of serotype in 402 Candida albicans isolates from the United States. Antimicrob Agents Chemother (1982) 3.91
Effect of the laccase gene CNLAC1, on virulence of Cryptococcus neoformans. J Exp Med (1996) 3.76
Factors influencing killing of Cryptococcus neoformans by human leukocytes in vitro. J Infect Dis (1972) 3.75
Practice guidelines for diseases caused by Aspergillus. Infectious Diseases Society of America. Clin Infect Dis (2000) 3.70
Distribution of alpha and alpha mating types of Cryptococcus neoformans among natural and clinical isolates. Am J Epidemiol (1978) 3.55
Control for rheumatoid factor in the latex test for cryptococcosis. Am J Clin Pathol (1971) 3.47
The role of the classical and alternate complement pathways in host defenses against Cryptococcus neoformans infection. J Immunol (1974) 3.38
A new species of Filobasidiella, the sexual state of Cryptococcus neoformans B and C serotypes. Mycologia (1977) 3.28
Phenoloxidase activity and virulence in isogenic strains of Cryptococcus neoformans. Infect Immun (1982) 3.13
Capsular polysaccharides of Cryptococcus neoformans. Rev Infect Dis (1984) 3.10
Biochemical studies of phenoloxidase and utilization of catecholamines in Cryptococcus neoformans. J Bacteriol (1982) 2.98
Genetic evidence for role of extracellular proteinase in virulence of Candida albicans. Infect Immun (1985) 2.91
Amphotericin B pharmacokinetics in humans. Antimicrob Agents Chemother (1978) 2.79
The developmentally regulated alb1 gene of Aspergillus fumigatus: its role in modulation of conidial morphology and virulence. J Bacteriol (1998) 2.78
TP53 mutations and hepatocellular carcinoma: insights into the etiology and pathogenesis of liver cancer. Oncogene (2007) 2.71
The second capsule gene of cryptococcus neoformans, CAP64, is essential for virulence. Infect Immun (1996) 2.67
Chromosomal rearrangement in Candida stellatoidea results in a positive effect on phenotype. Infect Immun (1991) 2.52
Creatinine metabolism in Cryptococcus neoformans and Cryptococcus bacillisporus. J Bacteriol (1980) 2.52
A developmentally regulated gene cluster involved in conidial pigment biosynthesis in Aspergillus fumigatus. J Bacteriol (1999) 2.50
Disseminated cryptococcosis in man: decreased lymphocyte transformation in response to Cryptococcus neoformans. J Infect Dis (1973) 2.45
Growth of Cryptococcus neoformans within human macrophages in vitro. Infect Immun (1973) 2.39
Molecular and genetic analysis of URA5 transformants of Cryptococcus neoformans. Infect Immun (1992) 2.32
Deletion of the Candida glabrata ERG3 and ERG11 genes: effect on cell viability, cell growth, sterol composition, and antifungal susceptibility. Antimicrob Agents Chemother (1995) 2.32
Restriction fragment polymorphism in mitochondrial DNA of Cryptococcus neoformans. J Gen Microbiol (1989) 2.28
Fungemia with compromised host resistance. A study of 70 cases. Ann Intern Med (1974) 2.25
Galactomannan antigenemia and antigenuria in aspergillosis: studies in patients and experimentally infected rabbits. J Infect Dis (1987) 2.18
Pharmacological studies with 5-fluorocytosine. Antimicrob Agents Chemother (1972) 2.14
Comparison of the electrophoretic karyotypes and chromosomal location of ten genes in the two varieties of Cryptococcus neoformans. Microbiology (1994) 2.14
Detection of Candida antigen in sera of patients with candidiasis by an enzyme-linked immunosorbent assay-inhibition technique. J Clin Microbiol (1979) 2.13
DNA probe for strain typing of Cryptococcus neoformans. J Clin Microbiol (1992) 2.12
Intravascular catheter exchange and duration of candidemia. NIAID Mycoses Study Group and the Candidemia Study Group. Clin Infect Dis (1995) 2.11
Cryptococcus neoformans serotype A glucuronoxylomannan-protein conjugate vaccines: synthesis, characterization, and immunogenicity. Infect Immun (1991) 2.11
Isolation of the third capsule-associated gene, CAP60, required for virulence in Cryptococcus neoformans. Infect Immun (1998) 2.10
Studies on Emmonsiella capsulata (Histoplasma capsulatum). II. Distribution of the two mating types in 13 endemic states of the United States. Am J Epidemiol (1974) 2.06
New, special stain for histopathological diagnosis of cryptococcosis. J Clin Microbiol (1981) 2.04
Aspergillus nidulans infection in chronic granulomatous disease. Medicine (Baltimore) (1998) 2.03
5-fluorocytosine resistance in Cryptococcus neoformans. Antimicrob Agents Chemother (1973) 2.00
Clotrimazole: new drug for systemic mycoses? Ann Intern Med (1970) 1.99
Abnormalities in cell-mediated immunity in patients with Cryptococcus neoformans infection. J Allergy Clin Immunol (1975) 1.99
Invasive aspergillosis. Absence of detectable antibody response. Am Rev Respir Dis (1971) 1.96
IL-12 prevents mortality in mice infected with Histoplasma capsulatum through induction of IFN-gamma. J Immunol (1995) 1.94
Successful treatment of Paecilomyces varioti infection in a patient with chronic granulomatous disease and a review of Paecilomyces species infections. Clin Infect Dis (1992) 1.84
Concentrations of airborne Aspergillus compared to the incidence of invasive aspergillosis: lack of correlation. Med Mycol (1998) 1.83
Biochemical differences between serotypes of Cryptococcus neoformans. Sabouraudia (1978) 1.83
Complement depletion in cryptococcal sepsis. J Immunol (1978) 1.82
Isolation, characterization, and localization of a capsule-associated gene, CAP10, of Cryptococcus neoformans. J Bacteriol (1999) 1.79
Physical and genetic mapping of Candida albicans: several genes previously assigned to chromosome 1 map to chromosome R, the rDNA-containing linkage group. Infect Immun (1991) 1.79
Rapid method to extract DNA from Cryptococcus neoformans. J Clin Microbiol (1991) 1.78
Serology of human cryptococcosis. Ann Intern Med (1968) 1.78
Candida albicans in patients with the acquired immunodeficiency syndrome: absence of a novel of hypervirulent strain. J Infect Dis (1990) 1.77
Fluconazole resistance associated with drug efflux and increased transcription of a drug transporter gene, PDH1, in Candida glabrata. Antimicrob Agents Chemother (1998) 1.76
Purification and characterisation of an extracellular serine proteinase from Aspergillus fumigatus and its detection in tissue. J Med Microbiol (1990) 1.76
Genome variation in Cryptococcus gattii, an emerging pathogen of immunocompetent hosts. MBio (2011) 1.76
Structural studies on the major, capsular polysaccharide from Cryptococcus bacillisporus serotype B. Carbohydr Res (1980) 1.74
Melanogenesis in Cryptococcus neoformans. J Gen Microbiol (1988) 1.73
Chemotherapy of systemic mycoses (second of two parts). N Engl J Med (1974) 1.73
Standardization of a fluconazole bioassay and correlation of results with those obtained by high-pressure liquid chromatography. Antimicrob Agents Chemother (1991) 1.72
Cryptococcus neoformans STE12alpha regulates virulence but is not essential for mating. J Exp Med (2000) 1.71
Selection of ura5 and ura3 mutants from the two varieties of Cryptococcus neoformans on 5-fluoroorotic acid medium. J Med Vet Mycol (1992) 1.71
High prevalence of Cryptococcus neoformans var. gattii in tropical and subtropical regions. Zentralbl Bakteriol Mikrobiol Hyg A (1984) 1.68
Nutritional physiology and taxonomy of human-pathogenic Cladosporium-Xylohypha species. J Med Vet Mycol (1996) 1.67
On the structure of the capsular polysaccharide from Cryptococcus neoformans serotype C. Immunochemistry (1978) 1.66
Cryptococcus neoformans CAP59 (or Cap59p) is involved in the extracellular trafficking of capsular glucuronoxylomannan. Eukaryot Cell (2004) 1.64
Flucytosine and amphotericin B: hemodialysis effects on the plasma concentration and clearance. Studies in man. Ann Intern Med (1974) 1.63
Experience with a new skin test antigen prepared from Cryptococcus neoformans. Am Rev Respir Dis (1968) 1.62
Protected environments and prophylactic antibiotics. A prospective controlled study of their utility in the therapy of acute leukemia. N Engl J Med (1973) 1.61